Lynx Dx, a diagnostics company based in Ann Arbor, Michigan, announced on May 5, 2026, that its MPS2-AS urine test performed comparably to MRI in identifying prostate cancer upgrading in men on active surveillance. The findings come from a clinical validation study presented at a major urology conference.
The study evaluated the test's ability to detect Gleason grade group upgrading, a key indicator of cancer progression. According to the company, MPS2-AS demonstrated high accuracy in guiding the need for surveillance biopsies, potentially reducing unnecessary invasive procedures.
Active surveillance is a standard approach for low-risk prostate cancer, where patients are monitored regularly rather than treated immediately. Current monitoring often involves periodic biopsies and MRIs, which can be costly and invasive. Lynx Dx's urine-based test offers a non-invasive alternative that could streamline follow-up care.
The company plans to make MPS2-AS available to urologists and patients later this year, pending regulatory clearances. Further studies are ongoing to validate the test in larger, diverse populations.
